We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+11.88%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$3.92B
AUM Growth
-$2.46M
Cap. Flow
-$105M
Cap. Flow %
-2.67%
Top 10 Hldgs %
77.48%
Holding
132
New
21
Increased
29
Reduced
29
Closed
20
Avg Time Held Equity + Options
7 quarters
Top 10 Avg Time Held Equity + Options
4.2 quarters
Top 20 Avg Time Held Equity + Options
7.5 quarters
Avg Time Held Equity only
7.1 quarters
Top 10 Avg Time Held Equity only
7.2 quarters
Top 20 Avg Time Held Equity only
9.1 quarters

Top Buys

Rank Stock Value
1
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$103M
2
CGEM icon
Cullinan Oncology
CGEM
+$22.5M
3
RNAM
Avidity Biosciences
RNAM
+$18.8M
4
VERA icon
Vera Therapeutics
VERA
+$16.3M
5
JBIO icon
Jade Biosciences
JBIO
+$15.3M

Top Sells

Rank Stock Value
1
CAVA icon
CAVA Group
CAVA
+$232M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$29.5M
3
VKTX icon
Viking Therapeutics
VKTX
+$20.8M
4
ALPN icon
Alpine Immune Sciences Inc
ALPN
+$16.1M
5
ONC icon
BeOne Medicines Ltd
ONC
+$15.6M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 56.02%
2 Healthcare 41.9%
3 Technology 0.98%
4 Miscellaneous 0.71%
5 Financials 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
NOW icon
76
ServiceNow
NOW
$146B
$1.97M 0.05%
+12,500
New +$1.83M
2024 Q2
0 quarters
OVID icon
77
Ovid Therapeutics
OVID
$480M
$1.92M 0.05%
2,500,000
– –
2020 Q3
15 quarters
GRTS icon
78
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$1.87M 0.05%
3,030,952
+2,000,000
+194% +$1.69M
2024 Q1
1 quarter
PEPG icon
79
PepGen
PEPG
$181M
$1.81M 0.05%
113,317
-86,683
-43% -$1.24M
2024 Q1
1 quarter
PANW icon
80
Palo Alto Networks
PANW
$343B
$1.53M 0.04%
9,000
+3,000
+50% +$449K
2024 Q1
1 quarter
PYPL icon
81
CALL
PayPal
PYPL
$47.5B
$1.51M 0.04%
26,000
-32,000
-55% -$2.04M
2023 Q3
3 quarters
KYTX icon
82
Kyverna Therapeutics
KYTX
$395M
$1.5M 0.04%
200,000
– –
2024 Q1
1 quarter
QCOM icon
83
Qualcomm
QCOM
$187B
$1.49M 0.04%
+7,500
New +$1.42M
2024 Q2
0 quarters
JBIO icon
84
Jade Biosciences
JBIO
$915M
$1.34M 0.03%
+23,131
New +$15.3M
2024 Q2
0 quarters
GOOGL icon
85
Alphabet (Google) Class A
GOOGL
$4.3T
$1.28M 0.03%
7,000
– –
2023 Q2
4 quarters
MGX icon
86
Metagenomi Therapeutics
MGX
$37.8M
$1.22M 0.03%
300,000
– –
2024 Q1
1 quarter
TRML icon
87
DELISTED
Tourmaline Bio
TRML
$1.18M 0.03%
91,426
-223,070
-71% -$3.59M
2021 Q2
12 quarters
RBRK icon
88
Rubrik
RBRK
$25.9B
$1.07M 0.03%
+35,000
New +$1.15M
2024 Q2
0 quarters
KRON icon
89
DELISTED
Kronos Bio
KRON
$1.05M 0.03%
842,954
– –
2020 Q4
14 quarters
MDB icon
90
MongoDB
MDB
$31.1B
$1.01M 0.03%
4,021
+2,021
+101% +$638K
2023 Q4
2 quarters
EDU icon
91
New Oriental
EDU
$9.09B
$972K 0.02%
12,500
-2,500
-17% -$204K
2024 Q1
1 quarter
BZ icon
92
Kanzhun
BZ
$6.89B
$941K 0.02%
+50,000
New +$1.01M
2024 Q2
0 quarters
FROG icon
93
JFrog
FROG
$12.6B
$939K 0.02%
+25,000
New +$916K
2024 Q2
0 quarters
PYPL icon
94
PayPal
PYPL
$47.5B
$870K 0.02%
15,000
+5,000
+50% +$318K
2023 Q3
3 quarters
INTC icon
95
Intel
INTC
$553B
$774K 0.02%
+25,000
New +$819K
2024 Q2
0 quarters
IRWD icon
96
Ironwood Pharmaceuticals
IRWD
$631M
$721K 0.02%
110,532
– –
2013 Q2
44 quarters
PEGA icon
97
Pegasystems
PEGA
$5.86B
$696K 0.02%
23,000
– –
2023 Q3
3 quarters
SNOW icon
98
Snowflake
SNOW
$130B
$682K 0.02%
5,051
-1,449
-22% -$214K
2024 Q1
1 quarter
ACHL
99
DELISTED
Achilles Therapeutics
ACHL
$616K 0.02%
755,375
– –
2021 Q1
13 quarters
CFLT icon
100
DELISTED
Confluent
CFLT
$561K 0.01%
19,000
– –
2023 Q4
2 quarters
2 3
4
5 6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q2 2024 Portfolio in Review

As of Q2 2024, Artal Group held 132 positions worth $3.92B, down 0.06% from $3.93B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Artal Group's Q2 2024 filing shows 21 new, 29 increased, 29 reduced and 20 closed positions. Its largest new stake was Cullinan Oncology: 1,057,949 shares worth $18.5M. The largest sale was CAVA Group, an estimated $232M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 56% of assets, up from 48% a quarter earlier, followed by Healthcare and Technology.

  • Artal Group's largest Q2 2024 buy was Cullinan Oncology: 1,057,949 shares worth $18.5M.
  • Artal Group added most to Lexicon Pharmaceuticals in Q2 2024, an estimated $103M increase.
  • Artal Group's biggest Q2 2024 reduction was CAVA Group, cutting an estimated $232M.
  • Artal Group fully exited Madrigal Pharmaceuticals in Q2 2024, selling an estimated $29.5M.
  • Artal Group's ten largest holdings make up 77% of its $3.92B portfolio in Q2 2024.
  • Artal Group opened 21 new positions and closed 20 in Q2 2024.
  • Artal Group's portfolio value fell 0.06% quarter-over-quarter to $3.92B.

Based on Artal Group's 13F filing for Q2 2024, filed 14 Aug 2024.